Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Her2-negative Tumor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02971761
What this trial is testing

Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer

Who this might be right for
Androgen Receptor PositiveEstrogen Receptor NegativeHER2/Neu Negative+3 more
City of Hope Medical Center 18
Large-scale testing (Phase 3)Study completedNCT02126449
What this trial is testing

DIetary REstriction as an Adjunct to Neoadjuvant ChemoTherapy for HER2 Negative Breast Cancer

Who this might be right for
Fasting Mimicking DietBreast CancerNeoadjuvant Chemotherapy+1 more
Leiden University Medical Center 131
Not applicableStudy completedNCT02403869
What this trial is testing

Quality of Life in Metastatic Breast Cancer (MBC) Patients in Second Line Monochemotherapy

Who this might be right for
Breast Neoplasms
Celgene 149
Early research (Phase 1)Ended earlyNCT01149356
What this trial is testing

RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor PositiveHER2/Neu NegativeMale Breast Carcinoma+4 more
National Cancer Institute (NCI) 15
Testing effectiveness (Phase 2)Study completedNCT02441946
What this trial is testing

A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer

Who this might be right for
Breast CancerHormone Receptor Positive TumorEarly-Stage Breast Carcinoma
Eli Lilly and Company 224
Testing effectiveness (Phase 2)WithdrawnNCT03872505
What this trial is testing

Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer

Who this might be right for
Breast CancerTriple Negative Breast Cancer
Cedars-Sinai Medical Center
Very early researchStudy completedNCT03599453
What this trial is testing

Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer

Who this might be right for
Triple -Negative Breast CancerEstrogen Receptor NegativeHER2/Neu Negative+2 more
Roswell Park Cancer Institute 8
Testing effectiveness (Phase 2)UnknownNCT05335473
What this trial is testing

Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure

Who this might be right for
HR Positive HER2 Negative Advanced Breast Cancer
Henan Cancer Hospital 87
Large-scale testing (Phase 3)Active Not RecruitingNCT01805271
What this trial is testing

Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy

Who this might be right for
Primary Non-metastatic Breast CancerWho Remain Disease-free
UNICANCER 1,278
Testing effectiveness (Phase 2)Study completedNCT02258451
What this trial is testing

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
Bayer 283
Testing effectiveness (Phase 2)WithdrawnNCT01913067
What this trial is testing

Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC

Who this might be right for
Brain MetastasisBreast CancerNon Small Cell Lung Cancer
Jules Bordet Institute
Not applicableNot Yet RecruitingNCT06950671
What this trial is testing

Role of Triggering Receptor Expressed on Myeloid Cells (TREM-1) as a Novel Biomarker in Human Epidermal Growth Factor Receptor -2 (HER-2) Negative Breast Cancer: a Molecular and Clinical Study

Who this might be right for
Breast Cancer Stage IBreast Cancer Stage IIBreast Cancer Stage III+1 more
Rahma Esam Salama Esawi 1
Testing effectiveness (Phase 2)Looking for participantsNCT05594095
What this trial is testing

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Who this might be right for
Breast NeoplasmBreast CancerHormone Receptor Positive Tumor+2 more
Fudan University 620
Early research (Phase 1)Study completedNCT04176757
What this trial is testing

ZN-c5 in Participants With Breast Cancer

Who this might be right for
Breast Cancer
Zeno Alpha Inc. 35
Post-approval studies (Phase 4)WithdrawnNCT03988114
What this trial is testing

Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Eli Lilly and Company
Testing effectiveness (Phase 2)Active Not RecruitingNCT04053322
What this trial is testing

Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.

Who this might be right for
ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancera Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status
UNICANCER 172
Not applicableUnknownNCT03617341
What this trial is testing

Brain Monitoring for High Risk of Brain Metastases in Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer With HER2 PositiveTriple Negative Breast Cancer
Yonsei University 200
Large-scale testing (Phase 3)UnknownNCT05673629
What this trial is testing

Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer

Who this might be right for
Breast Cancer
Beijing Biostar Pharmaceuticals Co., Ltd. 552
Testing effectiveness (Phase 2)Ended earlyNCT03070002
What this trial is testing

Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells

Who this might be right for
Breast Carcinoma Metastatic in the BoneCirculating Tumor Cell CountEstrogen Receptor Positive+3 more
Northwestern University 1
Large-scale testing (Phase 3)Study completedNCT00493870
What this trial is testing

TAC Versus TC for Adjuvant Breast Cancer

Who this might be right for
Breast Cancer
US Oncology Research 1,961
Next Page